Clara Bloomfield D MD


Clara Bloomfield D MD
ProfessorCollege of Medicinebloomfield.28@osu.edu
1216 James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7518Fax: (614) 366-1637
  • Leukemia Research

Research Description

After serving as director of the OSU Comprehensive Cancer Center from 1997 to July 2003, Dr. Bloomfield became Senior Advisor to the OSU cancer program and the charter member of the OSU Cancer Scholars Program, which is designed to help recruit and retain senior cancer investigators of international stature. Bloomfield is renowned for her more than three decades of research in adult leukemia and lymphoma, research that has been described in more than 600 publications and which has helped change standards of treatment. Bloomfield earned her MD from the University of Chicago and completed training in internal medicine and medical oncology at the University of Minnesota, where she became a full professor in seven years. In 1989 she became professor of medicine and chief of the Division of Oncology at the State University of New York at Buffalo, as well as chair of the Division of Medicine at Roswell Park Cancer Institute. She came to Ohio State in 1997, and in 2000 she was elected to the Institute of Medicine of the National Academy of Sciences. At the OSUCCC, she serves as cancer scholar and senior adviser. She is also a member of the Molecular Biology and Cancer Genetics Program, a professor of internal medicine and holder of the William Greenville Pace III Endowed Chair in Cancer Research.

Current Publications

  • Burchard EG, Torgerson DG, Yue F, Wang Y, Pui CH, Jeha S, Relling MV, Evans WE, Gerhard DS, Loh ML, Willman CL, Hunger SP, Mullighan CG, Yang JJ, Perez-Andreu V, Roberts KG, Xu H, Smith C, Zhang H, Yang W, Harvey RC, Payne-Turner D, Devidas M, Cheng IM, Carroll WL, Heerema NA, Carroll AJ, Raetz EA, Gastier-Foster JM, Marcucci G, Bloomfield CD, Mrózek K, Kohlschmidt J, Stock W, Kornblau SM, Konopleva M, Paietta E, Rowe JM, Luger SM, Tallman MS, Dean MA genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.Blood in press 12/2/2014
  • Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CDPrognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia.Leukemia in press 9/10/2014
  • Becker H, Maharry K, Mrózek K, Volinia S, Eisfeld AK, Radmacher MD, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Mendler JH, Wu YZ, Nicolet D, Paschka P, Powell BL, Carter TH, Wetzler M, Kolitz JE, Carroll AJ, Baer MR, Caligiuri MA, Stone RM, Marcucci G, Bloomfield CDPrognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.Leukemia 28 1754-8 8/1/2014
  • Powell BL, Koval G, Gulati K, Holowka N, Larson RA, Tallman MS, Appelbaum FR, Sher D, Willman C, Paietta E, Stock W, Poiré X, Moser BK, Gallagher RE, Laumann K, Bloomfield CDArsenic trioxide in front-line therapy of acute promyelocytic leukemia (C9710): prognostic significance of FLT3 mutations and complex karyotype.Leuk Lymphoma 55 1523-32 7/1/2014
  • Whitman SP, Kohlschmidt J, Maharry K, Volinia S, Mrózek K, Metzeler KH, Mendler JH, Eisfeld AK, Carroll AJ, Powell BL, Carter TH, Baer MR, Kolitz JE, Park IK, Stone RM, Caligiuri MA, Marcucci G, Bloomfield CD, Nicolet D, Schwind S, Becker HGAS6 expression identifies high-risk adult AML patients: potential implications for therapy.Leukemia 28 1252-8 6/1/2014
  • Maharry KS, Schneider S, Ksienzyk B, Mellert G, Pastore F, Dufour A, Benthaus T, Metzeler KH, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster ECombined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.J Clin Oncol 32 1586-94 5/20/2014
  • Bloomfield CD, de la Chapelle A, Eisfeld AK, Schwind S, Patel R, Huang X, Santhanam R, Walker CJ, Markowitz J, Hoag KW, Jarvinen TM, Leffel B, Perrotti D, Carson WE 3rd, Marcucci GIntronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.Sci Signal 7 ra36 4/15/2014
  • Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon RImplications of the miR-10 family in chemotherapy response of NPM1-mutated AML.Blood 123 2412-5 4/10/2014
  • Kolitz JE, George SL, Benson DM Jr, Maharry K, Marcucci G, Vij R, Powell BL, Allen SL, Deangelo DJ, Shea TC, Stock W, Bakan CE, Hars V, Hoke E, Bloomfield CD, Caligiuri MA, Larson RA, Alliance for Clinical Trials in OncologyRecombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.Cancer 120 1010-7 4/1/2014
  • Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Alachkar H, Santhanam R, Garzon R, Bloomfield CD, Marcucci GSPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome.J Clin Invest 124 1512-24 4/1/2014
  • Markowitz J, Duan W, Otterson GA, Carson WE 3rd, Marcucci G, Bloomfield CD, de la Chapelle A, Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang XNRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.Proc Natl Acad Sci U S A 111 4179-84 3/18/2014
  • Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CDEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.J Clin Oncol 32 548-56 2/20/2014
  • Mendler JH, Marcucci G, Bloomfield CDReply to "Rare coincident NPM1 and RUNX1 mutations in intermediate risk acute myeloid leukemia display similar patterns to single mutated cases". Haematologica 2014;99(2):e20-21.Haematologica 99 e22 2/1/2014
  • Wetzler M, Mrózek K, Kohlschmidt J, Dombret H, Döhner H, Pilorge S, Krug U, Carroll AJ, Larson RA, Marcucci G, Hiddemann W, Büchner T, Bloomfield CDIntensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification.Haematologica 99 308-13 2/1/2014
  • Wetzler M, Watson D, Stock W, Koval G, Mulkey FA, Hoke EE, McCarty JM, Blum WG, Powell BL, Marcucci G, Bloomfield CD, Linker CA, Larson RAAutologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).Haematologica 99 111-5 1/1/2014
  • Woods WG, Franklin AR, Alonzo TA, Gerbing RB, Donohue KA, Othus M, Horan J, Appelbaum FR, Estey EH, Bloomfield CD, Larson RAOutcome of adolescents and young adults with acute myeloid leukemia treated on COG trials compared to CALGB and SWOG trials.Cancer 119 4170-9 12/1/2013
  • Birger Y, Hannah RL, Kinston SJ, Schütte J, Beck D, Knezevic K, Schiby G, Jacob-Hirsch J, Biran A, Kloog Y, Marcucci G, Bloomfield CD, Aplan PD, Pimanda JE, Göttgens B, Izraeli S, Goldberg L, Tijssen MRGenome-scale expression and transcription factor binding profiles reveal therapeutic targets in transgenic ERG myeloid leukemia.Blood 122 2694-703 10/10/2013
  • Gupta P, Mulkey F, Hasserjian RP, Sanford BL, Vij R, Hurd DD, Odenike OM, Bloomfield CD, Owzar K, Stone RM, Larson RA, Alliance for Clinical Trials in OncologyA phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).Invest New Drugs 31 1311-20 10/1/2013
  • Metzeler KH, Caligiuri MA, Marcucci G, Bloomfield CD, Maharry K, Kohlschmidt J, Volinia S, Mrózek K, Becker H, Nicolet D, Whitman SP, Mendler JH, Schwind S, Eisfeld AK, Wu YZ, Powell BL, Carter TH, Wetzler M, Kolitz JE, Baer MR, Carroll AJ, Stone RMA stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia.Leukemia 27 2023-31 10/1/2013
  • Katz ML, Ferketich AK, Paskett ED, Bloomfield CDHealth literacy among the Amish: measuring a complex concept among a unique population.J Community Health 38 753-8 8/1/2013
  • Mendler JH, Maharry K, Becker H, Eisfeld AK, Senter L, Mrózek K, Kohlschmidt J, Metzeler KH, Schwind S, Whitman SP, Khalife J, Caligiuri MA, Klisovic RB, Moore JO, Carter TH, Marcucci G, Bloomfield CDIn rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.Haematologica 98 e92-4 8/1/2013
  • Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Stone RM, Thompson JE, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Westervelt P, Wheeler B, Shead DA, Naganuma MMyelodysplastic syndromes: clinical practice guidelines in oncology.J Natl Compr Canc Netw 11 838-74 7/1/2013
  • Willman CL, Bloomfield CD, Paietta E, Gallagher RE, Park JH, Rowe JM, Wiernik PH, Tallman MS, Douer D, Zickl LN, Schiffer CA, Appelbaum FR, Feusner JH, Shepherd LAll-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129.Leuk Res 37 795-801 7/1/2013
  • Mrózek K, Nicolet D, Maharry KS, Carroll AJ, Marcucci G, Bloomfield CDReply to K. Orendi et al.J Clin Oncol 31 2361-2 6/20/2013
  • Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD, Marcucci GClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.J Clin Oncol 31 2086-93 6/10/2013
  • Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci GTargeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.Clin Cancer Res 19 2355-67 5/1/2013
  • Walker A, Mrózek K, Kohlschmidt J, Rao KW, Pettenati MJ, Sterling LJ, Marcucci G, Carroll AJ, Bloomfield CD, Alliance for Clinical Trials in OncologyNew recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.Genes Chromosomes Cancer 52 385-401 4/1/2013
  • Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci GIncreased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.Leukemia 27 871-8 4/1/2013
  • Li Z, Herold T, He C, Chen J, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Büchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Döhner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SKIdentification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.J Clin Oncol 31 1172-81 3/20/2013
  • Larson RA, Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, Kolitz JE, Powell BL, Voorhees P, Wang ES, Blum W, Stone RM, Marcucci G, Bloomfield CD, Moser BBortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.J Clin Oncol 31 923-9 3/1/2013
  • Li J, Xu C, Wang L, Zhou M, Jiang M, Zhou J, Caligiuri MA, Nervi C, Bloomfield CD, Marcucci G, Yu L, Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou LEpigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.Blood 121 499-509 1/17/2013
  • Edwards CG, Nicolet D, Mrózek K, Maharry K, Wu YZ, Paschka P, Eisfeld AK, Hoellerbauer P, Becker H, Metzeler KH, Curfman J, Kohlschmidt J, Prior TW, Kolitz JE, Blum W, Pettenati MJ, Dal Cin P, Carroll AJ, Caligiuri MA, Schwind S, Larson RA, Volinia S, Marcucci G, Bloomfield CD, Alliance for Clinical Trials in Oncologyinv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.Blood 121 385-91 1/10/2013
  • Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci G, Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZLenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.Blood 121 159-69 1/3/2013
  • Stock W, Johnson JL, Stone RM, Kolitz JE, Powell BL, Wetzler M, Westervelt P, Marcucci G, DeAngelo DJ, Vardiman JW, McDonnell D, Mrózek K, Bloomfield CD, Larson RADose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.Cancer 119 90-8 1/1/2013

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu